Dr. Ajebo is a board-certified dermatologist in the MedStar Health Department of Dermatology and an Assistance Professor at Georgetown University School of Medicine. She obtained her medical degree at the Medical College of Georgia, Augusta University, where she also compelted her internship and dermatology residency.  Her clinical interest includes pigmented lesions, melanoma, and non-melanoma skin cancers. She is a member of American Academy of Dermatology. 

Dr. Atkins began his career at Tufts before moving to Beth Israel Deaconess Medical Center and being appointed Professor at Harvard Medical School where he served as Deputy Chief of the Division of Hematology/Oncology and leader of the Biologic Therapy and Cutaneous Oncology Programs, Co-PI of the Harvard Skin Cancer SPORE, founding leader of the DF/HCC Kidney Cancer Program and Director of the DF/HCC Kidney Cancer SPORE.  In 2012, he moved to Georgetown where he is Deputy Director of the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC and William Scholl Professor and Vice Chair of the Department of Oncology at Georgetown University Medical Center. He leads the Lombardi Immunotherapy/Heme Working Group and Chairs the IIT Steering Committee. His current research focuses on immunotherapy for melanoma and RCC and biomarkers for response and toxicity. He has published over 500 articles (H-Index 134) and 5 books and has lectured extensively on these topics.  He is past president of SITC, and past member of the NIH Recombinant DNA Advisory Council and the ASCO Nominating Committee. Currently he co-Chairs the Melanoma Research Foundation Scientific Advisory Council and Chairs the Melanoma Research Alliance Clinical Advisory Board. He is a 2021 recipient of the OncLive Giant in Cancer Care Award for Melanoma and in 2022 received the Lifetime Achievement Award for Immunotherapy from SITC. He was recently inducted into SITC’s 2023 Class of Fellows of the Academy of Immuno-Oncology (FAIO) and in 2024 became a Fellow of ASCO (FASCO).

Min Deng, MD is an Associate Professor in the Department of Dermatology at MedStar Washington Hospital Center/Georgetown University Hospital. She serves as Director of Mohs Micrographic Surgery and Residency Program Director. Dr. Deng’s clinical interests include cutaneous oncology, Mohs micrographic surgery, surgical training, and graduate medical education. She is an active fellow of the American College of Mohs Surgery and member of the American Society for Dermatologic Surgery, Association of Professors of Dermatology, and American Academy of Dermatology.

Leonard has have been an oncology social worker at the Lombardi Comprehensive Cancer Center for the last 18 years.  He is certified in oncology social work and in palliative care social work. His passion is helping patients and those close to them navigate the difficult challenges and decisions that face them during all phases of their cancer treatment.

Kellie Gardner, CRNP, is an nurse practitioner specializing in medical oncology at MedStar Georgetown
University Hospital. Kellie received her undergraduate degree in nursing from
Lynchburg College. She went onto receive a master of science degree from
Georgetown University. Kellie is an oncology-certified nurse. 

Geoffrey T. Gibney, MD, is a co-leader of the Melanoma Disease Group at the Lombardi Comprehensive Cancer Center and MedStar Cancer Network, and a member of the Developmental Therapeutics (Phase I) program. He is well known for treating patients with advanced non-melanoma skin cancers (basal cell carcinoma, squamous cell carcinoma and merkel cell carcinoma), renal cell carcinoma and other rare skin cancers. Dr. Gibney is board certified in both internal medicine and medical oncology. He was previously a faculty member in the Department of Cutaneous Oncology at the Moffitt Cancer Center in Tampa.

Dr. Gibney is recognized for his advanced melanoma research. He is currently involved in several clinical trials focused on developing novel immunotherapy and targeted therapy strategies. Past clinical research has included the study of anti-PD-1 therapy to prevent recurrences of resected melanoma, combination immunotherapies (such as ipilimumab plus the novel IDO1 inhibitor, epacadostat) to enhance the clinical benefit in advanced melanoma patients and combination BRAF targeted therapy to overcome drug resistance.

His current goal is to develop biomarker-driven approaches for personalized therapeutic strategies in patients with advanced malignancies.

Dr. Giurintano is a fellowship-trained head and neck oncologic and microvascular reconstructive surgeon. He is an Assistant Professor in the Department of Otolaryngology – Head and Neck Surgery at MedStar Georgetown University Hospital. His practice focuses on treatment of malignant and benign diseases affecting the head and neck as well as complex reconstruction of head and neck defects using microvascular surgical techniques. He is part of the cutaneous malignancy team at MedStar Georgetown University Hospital.

Dr. Suthee Rapisuwon is a leading medical oncologist specializing in melanoma, with a particular focus on uveal melanoma. Dr. Rapisuwon is leading an investigator initiated clinical trial, the HCRN-MEL17-309 study, a Phase II multi-center trial investigating the combination of nivolumab and ipilimumab in patients with high-risk uveal melanoma. This research aims to enhance therapeutic strategies and improve patient outcomes for this aggressive form of eye cancer. Dr. Rapisuwon has recently presented significant findings at the 2024 ASCO Annual Meeting, contributing to the advancement of melanoma treatment and patient care.

Marcelo Sleiman Jr is a Program Manager in Cancer Prevention and Control at Georgetown Lombardi. He joined Dr. Tercyak in 2022 after graduating from the University of Virginia with a degree in Biostatistics. Mr. Sleiman has a particular interest in behavioral and preventive medicine, including the primary prevention of skin cancer. He manages multiple projects focusing on themes of youth and family cancer control, high-risk populations, and the study of health outcomes among marginalized and underserved communities. Mr. Sleiman intends to apply to medical school, enjoys exercising in his leisure time, and celebrates his Brazilian heritage through cooking.

Dr. Tercyak is a tenured Professor in the Departments of Oncology and Pediatrics at the Georgetown University School of Medicine. At Lombardi Comprehensive Cancer Center, Dr. Tercyak serves as Co-Leader of the NCI-designated Cancer Prevention and Control research program. He is a member of the Fisher Center for Hereditary Cancer and Clinical Genomics Research, a Senior Scholar at the Georgetown University Center for Child and Human Development and is on the faculty of the Department of Psychology. His research focuses on developmental and biobehavioral aspects of cancer risk, communication, and intervention, including public health genomics, tobacco control, and skin cancer prevention. He is the Principal Investigator of a new 5-year grant from the National Cancer Institute: it is a cluster-randomized trial of sun safety prevention for young children and their families living in rural and underserved communities.

Dr. Ruiz de Luzuriaga is a board certified dermatologistand dermatopathologist. She is interested in epidemiologic studies in dermatology anddermatopathology, clinical informatics, and the use of information technology for theimprovement of patient care, diagnosis and treatment algorithms, quality improvement,and medical education. Her clinical focus is on total body photography, dermatoscopy,skin cancer surveillance, and melanoma prevention and early detection. She hopes toexplore the decision-making experience surrounding ambiguous melanocytic neoplasms, andhow patients and dermatologists incorporate additional data from novelancillary diagnostic tests for melanocytic lesions.

Jeffrey Whitridge is a medical professional that works in the field of nutrition.  He has been practicing clinical nutrition and dietetics for over 25 years.  Jeffrey has been monitoring and surveilling his skin and mole integrity for over 20 years.  Jeffrey enjoys being active, travel and of course eats a plant forward diet.

Dr. Allison Betof Warner is Director of the Melanoma Program, Director of Solid Tumor Cellular Therapy, and Mark & Mary Stevens Endowed Scholar in Melanoma at Stanford Cancer Institute. Dr. Betof completed her MD and PhD at Duke University, Internal Medicine residency at Massachusetts General Hospital (Harvard University) and Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Betof’s laboratory focuses on understanding resistance to immune checkpoint blockade and cellular therapies for melanoma and other solid tumors. She is the Principal Investigator of clinical trials exploring novel treatments for immunotherapy-refractory melanoma and is internationally recognized for her expertise in brain/CNS metastasis and the use of novel cellular therapies. Dr. Betof has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy for the treatment of melanoma and other solid tumors. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), and Melanoma Research Foundation.

Jamie lives in Tampa, Florida with his wife Angie. They have one son, Eric, a wonderful daughter in law Amy, and a beautiful 14 year old granddaughter.

Jamie had surgery to remove melanoma from his back in 2012 and was diagnosed with Stage 4B Metastatic Melanoma in 2014. He was accepted to the Stage 2 TIL Trial at Moffitt cancer Center in Tampa, Florida. Jamie’s tumors continue to recede and grow smaller and some have completely disappeared with nothing left but scar tissue. He has not had a bad check up since he started the TIL Trial in 2014. Jamie credits TIL, the incredible staff at Moffitt and his wonderful family for saving his life. 

Dr. Allison Betof Warner is Director of the Melanoma Program, Director of Solid Tumor Cellular Therapy, and Mark & Mary Stevens Endowed Scholar in Melanoma at Stanford Cancer Institute. Dr. Betof completed her MD and PhD at Duke University, Internal Medicine residency at Massachusetts General Hospital (Harvard University) and Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Betof’s laboratory focuses on understanding resistance to immune checkpoint blockade and cellular therapies for melanoma and other solid tumors. She is the Principal Investigator of clinical trials exploring novel treatments for immunotherapy-refractory melanoma and is internationally recognized for her expertise in brain/CNS metastasis and the use of novel cellular therapies. Dr. Betof has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy for the treatment of melanoma and other solid tumors. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), and Melanoma Research Foundation.

Jamie lives in Tampa, Florida with his wife Angie. They have one son, Eric, a wonderful daughter in law Amy, and a beautiful 14 year old granddaughter.

Jamie had surgery to remove melanoma from his back in 2012 and was diagnosed with Stage 4B Metastatic Melanoma in 2014. He was accepted to the Stage 2 TIL Trial at Moffitt cancer Center in Tampa, Florida. Jamie’s tumors continue to recede and grow smaller and some have completely disappeared with nothing left but scar tissue. He has not had a bad check up since he started the TIL Trial in 2014. Jamie credits TIL, the incredible staff at Moffitt and his wonderful family for saving his life. 

Donna is a retired masseuse and former Pilates teacher. Donna is a mother of two grown adult children. She is crazy about the NFL, enjoys playing tennis and watching sports. Donna is a melanoma survivor.

Jim Day is an artist and custom fabricator from Los Angeles. He is well known in his community as the guy who can build anything out of anything, and often helps others build things they could not build themselves. In 2021, Jim discovery he had a brain tumor, and was diagnosed with Stage 4 metastatic melanoma. After his diagnosis, Jim met with Dr. In whom informed him of his treatment options. Jim knew instantly when he spoke to Dr. In about oncolytic viruses that he wanted to work with him. Two years later Jim has lost an extraordinary amount of cancer, and his side effects are minimal. Jim says that because of Dr. In and the oncolytic virus therapies, he feels alive again. 

Gino K. In is a medical oncologist at the University of Southern California, who specializes in solid tumor and cutaneous oncology. He completed his oncology fellowship at the USC Keck School of Medicine and subsequently joined the USC Norris Comprehensive Cancer Center, where he oversees the multidisciplinary melanoma and skin cancer program, and leads clinical trials for melanoma, and other skin cancers, including cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma.

Dr.Rebecca Hartman is Associate Chief of the Dermatology section at VA BostonHealthcare System, Director of Melanoma Epidemiology at Brigham and Women’sHospital, and Assistant Professor of Dermatology at Harvard Medical School. Sheclinically specializes in caring for patients with melanoma and pigmentedlesions at Dana Farber Cancer Institute and practices medical dermatology at VABoston. In addition, she conducts melanoma epidemiologic and clinical researchfunded by the VA and Department of Defense, focusing on aggressive and raremelanomas.

Dr. Tara Mitchell is an Associate Professor of medicine at the University of Pennsylvania’s Perelman School of Medicine. She is the Section Chief of melanoma/sarcoma in the division of Hematology/Oncology at Penn's Abramson Cancer Center and the Director of Clinical Research for the Tara Miller Melanoma Center at Penn. Dr. Mitchell is board certified in both medical oncology and clinical pharmacology.

Dr. Sondak is Chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. He holds the Richard M. Schulze Family Foundation Distinguished Endowed Chair in Cutaneous Oncology, and is also a Professor in the Departments of Oncologic Sciences and Surgery at the University of South Florida Morsani College of Medicine. Since 2004, when he came to Tampa, the Cutaneous Oncology Clinic at Moffitt has grown into one of the largest multidisciplinary treatment centers for pediatric melanoma and related conditions in the world. Dr. Sondak has been a leader in studies of surgical treatment of melanoma and other cutaneous malignancies, particularly in the application of sentinel lymph node biopsy and lymph node dissection to the staging and treatment of melanoma, and has been instrumental in training many surgical oncologists in these techniques over the years. Dr. Sondak also has a strong research background: he served as Principal Investigator of the Moffitt Skin SPORE, a major NCI-funded “team science” grant conducting translational research in melanoma and other cutaneous malignancies. His research interests include surgical treatment of melanoma in adults and children; adjuvant (postoperative) and neoadjuvant (preoperative) therapy of melanoma; and evaluation of new therapies for patients with localized or disseminated melanoma.

Dr. Wuthrick is an Associate Member in radiation oncology at Moffitt Cancer Center and the Section Head for Cutaneous Radiation Oncology with clinical and research interests centered around cutaneous malignancies.  Dr. Wuthrick is the clinical director of radiation oncology at Moffitt Cancer, associate chair of Graduate Medical Education at Moffitt, and Chair of the NRG Oncology Radiation Oncology Committee.

Dr. Kluger is an internationally recognized expert on the disease she treats - melanoma and renal cell carcinoma (RCC). She engages in clinical and bench-based translational research, with a focus on developing novel therapies. Her lab has been continuously NIH-funded, and she has published in top-tier journals. She designs clinical trials with laboratory correlates resulting from her pre-clinical work, and she has been heavily involved in early phase development of immunotherapy regimens.

Dr. Alan Tan is director of the genitourinary oncology program at Rush University medical center and co-leads the precision medicine program.  He is co-chair of the Hoosier cancer research network melanoma working group.  He also serves as the genitourinary executive officer for the Alliance for Clinical Trials in Oncology.  His research interests include biomarker development for melanoma and genitourinary malignancies.